EP2377536

Methods of Using Sustained Release Aminopyridine Compositions

expired
JurisdiktionEP
Anmeldedatum11. Apr. 2005
Veröffentlichungsdatum17. Aug. 2022
Erteilungsdatum17. Aug. 2022
Ablaufdatum11. Apr. 2025
Veröffentlichungsnr.EP2377536
Anmeldenr.EP11160247
UPC-Verfahren6

Zusammenfassung

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Anmelder

ACORDA THERAPEUTICS INC [US]

Erfinder

BLIGHT ANDREW R [US]COHEN RON [US]

Externe Quellen

Klassifikation

IPC-Klassen
A61K 31/44
CPC-Klassen
A61K 31/435A61K 31/44A61K 31/4409A61K 9/20A61P 17/02A61P 19/08A61P 21/00A61P 25/00A61P 25/28A61P 43/00
AI: Life Sciences
warum

Acorda fampridine for MS — A61K31/44. Pure pharma.

Weitere Navigation
Entscheidungen
Rechtstexte
Analysen

Zu Sammlung hinzufügen

0 Einträge hinzufügen zu:

Anmeldung

Registrieren